• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Engineering antibody therapies for protective immunity.

作者信息

Lam Nora, Farber Donna L

机构信息

Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY.

Department of Surgery, Columbia University Irving Medical Center, New York, NY; Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY.

出版信息

J Thorac Cardiovasc Surg. 2021 Apr;161(4):1358-1361. doi: 10.1016/j.jtcvs.2020.05.107. Epub 2020 Jun 24.

DOI:10.1016/j.jtcvs.2020.05.107
PMID:32711969
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7311330/
Abstract
摘要

相似文献

1
Engineering antibody therapies for protective immunity.
J Thorac Cardiovasc Surg. 2021 Apr;161(4):1358-1361. doi: 10.1016/j.jtcvs.2020.05.107. Epub 2020 Jun 24.
2
Engineering Antibodies for the Treatment of Infectious Diseases.工程抗体治疗传染病。
Adv Exp Med Biol. 2017;1053:207-220. doi: 10.1007/978-3-319-72077-7_10.
3
Audio Interview: Planning for the SARS-CoV-2 Vaccine Rollout.音频访谈：SARS-CoV-2疫苗接种计划
N Engl J Med. 2021 Jan 7;384(1):e13. doi: 10.1056/NEJMe2100295.
4
Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.在 B 细胞耗竭患者中使用恢复期血浆成功治疗 COVID-19 感染可能会促进细胞免疫。
Eur J Immunol. 2021 Oct;51(10):2478-2484. doi: 10.1002/eji.202149277. Epub 2021 Sep 3.
5
Understanding the parameters guiding the best practice for treating B-cell-depleted patients with COVID-19 convalescent plasma therapy.了解指导使用新冠康复期血浆疗法治疗B细胞耗竭患者的最佳实践参数。
Br J Haematol. 2023 Jan;200(2):e25-e27. doi: 10.1111/bjh.18540. Epub 2022 Nov 10.
6
Therapeutic antibody gene transfer: an active approach to passive immunity.
Mol Ther. 2004 Sep;10(3):411-6. doi: 10.1016/j.ymthe.2004.06.865.
7
Resolution of Persistent COVID-19 After Convalescent Plasma in a Patient with B Cell Aplasia.B细胞发育不全患者接受恢复期血浆治疗后持续性新冠肺炎的缓解
J Clin Immunol. 2021 Jul;41(5):926-929. doi: 10.1007/s10875-021-00996-7. Epub 2021 Feb 20.
8
Not just antibodies: B cells and T cells mediate immunity to COVID-19.不仅是抗体：B 细胞和 T 细胞介导对 COVID-19 的免疫。
Nat Rev Immunol. 2020 Oct;20(10):581-582. doi: 10.1038/s41577-020-00436-4.
9
COVID-19: Herd immunity and convalescent plasma transfer therapy.新型冠状病毒肺炎：群体免疫与恢复期血浆输注疗法
J Med Virol. 2020 Sep;92(9):1380-1382. doi: 10.1002/jmv.25870. Epub 2020 Jul 11.
10
Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery.免疫功能低下患者的恢复期血浆介导的 SARS-CoV-2 病毒清除，无 B 细胞恢复。
Int J Mol Sci. 2021 Aug 18;22(16):8902. doi: 10.3390/ijms22168902.

引用本文的文献

1
Commentary: Providing optimal care for cardiothoracic patients of the future requires expertise spanning barriers of time and specialization.评论：为未来的心胸外科患者提供最佳护理需要跨越时间和专业壁垒的专业知识。
J Thorac Cardiovasc Surg. 2021 Apr;161(4):1363-1364. doi: 10.1016/j.jtcvs.2020.06.073. Epub 2020 Jun 29.

本文引用的文献

1
Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City.纽约市先前健康的儿童和青少年与 COVID-19 相关的多系统炎症综合征。
JAMA. 2020 Jul 21;324(3):294-296. doi: 10.1001/jama.2020.10374.
2
Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome.急性 COVID-19 心血管综合征的描述与处理建议。
Circulation. 2020 Jun 9;141(23):1903-1914. doi: 10.1161/CIRCULATIONAHA.120.047349. Epub 2020 Apr 16.
3
Effectiveness of convalescent plasma therapy in severe COVID-19 patients.恢复期血浆疗法治疗重症 COVID-19 患者的疗效。
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. doi: 10.1073/pnas.2004168117. Epub 2020 Apr 6.
4
CRISPR-engineered T cells in patients with refractory cancer.经 CRISPR 基因编辑的 T 细胞治疗难治性癌症的患者。
Science. 2020 Feb 28;367(6481). doi: 10.1126/science.aba7365. Epub 2020 Feb 6.
5
B cells engineered to express pathogen-specific antibodies protect against infection.经工程改造表达病原体特异性抗体的 B 细胞可预防感染。
Sci Immunol. 2019 May 17;4(35). doi: 10.1126/sciimmunol.aax0644.
6
CRISPR-Mediated Editing of the B Cell Receptor in Primary Human B Cells.CRISPR介导的原代人B细胞中B细胞受体的编辑
iScience. 2019 Feb 22;12:369-378. doi: 10.1016/j.isci.2019.01.032. Epub 2019 Feb 1.
7
Reprogramming the antigen specificity of B cells using genome-editing technologies.利用基因组编辑技术重编程 B 细胞的抗原特异性。
Elife. 2019 Jan 17;8:e42995. doi: 10.7554/eLife.42995.
8
Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements.CRISPR-Cas9 诱导的双链断裂的修复会导致大片段缺失和复杂重排。
Nat Biotechnol. 2018 Sep;36(8):765-771. doi: 10.1038/nbt.4192. Epub 2018 Jul 16.
9
Antibody therapies for the prevention and treatment of viral infections.用于预防和治疗病毒感染的抗体疗法。
NPJ Vaccines. 2017 Jul 10;2:19. doi: 10.1038/s41541-017-0019-3. eCollection 2017.
10
Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Congenital Heart Disease.确定先天性心脏病婴儿中重症呼吸道合胞病毒感染的风险及相关发病率和死亡率。
Infect Dis Ther. 2017 Mar;6(1):37-56. doi: 10.1007/s40121-016-0142-x. Epub 2017 Jan 9.